DOCSLIB.ORG

2017 Regional Chain Conference Strategic Partners Profiles FLOOR PLAN

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

February 5 - 7, 2017 • The Breakers • Palm Beach, FL 2017 Regional Chain Conference Strategic Partners Profiles FLOOR PLAN One-to-One Busines Conferences The Breakers, Ponce de Leon Ballroom One-To-One Business Conferences The Breakers, Ponce De Leon Ballroom 500 502 504 506 508 510 512 514 516 518 520 The Smith Drug Auburn Kimberly Alliance for ACON KeySource PharmaSmart Compliance Voicetech Capital Drug FLAVORx Company Pharma Clark Patient Laboratories Medical Team Medication Safety 117 216 217 316 317 416 417 Pharmacy Accreditation Teva Tri State H.D. QS/1 Quality Comar Commission Pharma Distribution Smith Solutions for Health Care 115 214 215 314 315 414 415 Scientific Lilly MarkeTouch Adheris Synergy Prescribe- Allergan Technologies USA Media Health Medical Wellness Corporation 113 212 213 312 313 412 413 Kirby Masters American Paramount Navajo Inc. Genetco PDR Lester Pharma Greetings RX 111 210 211 310 311 410 411 Pfizer Collegium BD Diabetes Worldwide Inmar Mirixa Innovation Alkermes Pharma Pharma 109 208 209 308 309 408 409 Change Provider- River City VoicePort Surescripts PerceptiMed iMedicare Healthcare Science 107 206 207 306 307 406 407 Amerisource Hallmark Ateb QuintilesIMS FDS Quidel Kloudscript Bergen Cards 105 204 205 304 305 404 405 Colgate - PDX-NHIN- Cardinal Bayer Scriptcycle Nielsen RelayHealth Palmolive RX.com Health Consumer 103 202 203 302 303 402 403 Upsher CoverMy- Absolute AR TCGRx Mondelez OrderInsite McKesson Smith Meds 101 200 201 300 301 400 401 Health- Takeda Pfizer Anda Centor Source ScriptPro Pharma SupplyLogix Consumer Distributors USA Entrance Entrance BOOTH ASSIGNMENTS BY COMPANY (As of January 5, 2017) Absolute AR .......................................... 103 Mondelez International ......................... 203 Accreditation Commission Navajo Incorporated ............................. 213 for Health Care ............................... 416 Nielsen .................................................. 305 Acon Laboratories Inc. .......................... 518 OrderInsite, LLC .................................... 302 Adheris Health....................................... 215 Paramount Rx ....................................... 313 Alkermes ............................................... 411 PDR ....................................................... 413 Allergan Inc. .......................................... 314 PDX-NHIN-Rx.com ............................... 204 Alliance For Patient Medication Safety . 516 PerceptiMed, Inc. .................................. 308 American Greetings Corporation .......... 213 Pfizer Consumer Healthcare ................. 200 AmerisourceBergen Corporation .......... 307 Pfizer Inc, orldwideW Pharmaceuticals . 210 Anda, Inc. .............................................. 101 Pharmacy Quality Solutions .................. 316 Ateb, Inc. ............................................... 107 PharmaSmart International ................... 502 Auburn Pharmaceutical ........................ 508 PrescribeWellness ................................. 415 Bayer Consumer Health ........................ 404 ProviderScience, LLC ........................... 409 BD Diabetes Care ................................. 111 QS/1 ...................................................... 117 Capital Drug .......................................... 512 Quidel Corporation................................ 306 Cardinal Health ..................................... 205 QuintilesIMS .......................................... 206 Centor ................................................... 201 RelayHealth ........................................... 405 Change Healthcare ............................... 408 River City Pharmaceutical Colgate-Palmolive Co. Inc. ................... 105 Distribution Inc. .............................. 109 Collegium Pharmaceutical, Inc. ............ 310 Scientific echnologiesT Corporation ..... 414 Comar, Inc. ............................................ 317 Scriptcycle LLC ..................................... 304 The Compliance Team, Inc. .................. 504 ScriptPro ............................................... 301 CoverMyMeds ....................................... 402 Smith Drug Company ........................... 500 FDS, Inc. ............................................... 207 Supplylogix LLC .................................... 401 FLAVORx ............................................... 514 Surescripts LLC .................................... 209 Genetco, Inc.......................................... 412 Synergy Medical ................................... 315 H. D. Smith ............................................ 417 Takeda Pharmaceuticals U.S.A., Inc. .... 400 Hallmark Cards, Inc. ............................. 406 TCGRx .................................................. 202 HealthSource Distributors ..................... 300 Teva Pharmaceuticals ........................... 216 iMedicare .............................................. 309 Tri State Distribution, Inc. ...................... 217 Inmar ..................................................... 211 Upsher-Smith Laboratories, Inc. ........... 303 Innovation ............................................. 410 VoicePort, LLC ...................................... 208 KeySource Medical, Inc. ....................... 520 VoiceTech .............................................. 506 Kimberly-Clark Corporation .................. 510 Kirby Lester ........................................... 113 Kloudscript, Inc. .................................... 407 Lilly USA, LLC ....................................... 115 MarkeTouch Media, Inc. ........................ 214 Masters Pharmaceutical, Inc. ............... 212 McKesson Corporation ......................... 403 Mirixa Corporation ................................ 311 COMPANY PROFILES (As of January 5, 2017) Absolute AR ...........................................................................103 101 Jim Wright Freeway S. Ste 200 Fort Worth, TX 76108-2202 Website: http://www.pdxinc.com Company Description: Absolute AR Accounts Receivable Services offers a full service pharmacy submission and transaction level reconciliation package to chain and independent pharmacies. Processing over 14 million claims monthly, Absolute AR unites claim submission reconciliation with revenue recovery and contract management. This level of sophistication and customer service is why thousands of pharmacies rely on Absolute AR. Top Products: Achieve (Rx), handles all of your reconciliation needs including paper and electronic remittances while working directly with your payers to receive every 835 file Acquire (Rx), provides a claims chasing service for unpaid, partial paid, overpaid, and questionable third party receivables Actual (Rx), offers reporting, tracking, and detailed analysis for reimbursement, PDM performance, and MAC dilemmas to give you leverage on future contract negotiations Assist (Rx), is a reconciliation service specifically for independent pharmacies and provides you with screen management reports so you can determine your weekly or monthly aging reports Assist (Rx) with Elite, is the same reconciliation service as the basic Assist (Rx) service, but is geared more toward multi store independents and includes a n account manager Appointment Contact: Ms. Beverely Hill Phone: (817) 367-4574 Fax: (817) 935-2024 Email: [email protected] Attending Individuals: Trinidad Lara, Sales Representative Email: [email protected] COMPANY PROFILES (As of January 5, 2017) Absolute AR (continued) .......................................................103 Attending Individuals (continued): Brooke Payne Martin, Director, Absolute(AR) Services Phone: (817) 246-6760 Email: [email protected] COMPANY PROFILES (As of January 5, 2017) Accreditation Commission for Health Care ........................416 139 Weston Oaks Ct Cary, NC 27513-2256 Website: http://www.achc.org Appointment Contact: Mr. Roy Bigler Phone: (919) 228-6558 Fax: (919) 785-3011 Email: [email protected] Attending Individuals: Roy Bigler, National Accounts Representative Phone: (919) 228-6558 Email: [email protected] COMPANY PROFILES (As of January 5, 2017) Acon Laboratories Inc. ..........................................................518 10125 Mesa Rim Rd San Diego, CA 92121-2915 Website: http://www.oncallmeters.com Company Description: Marketing and manufacturing rapid diagnostic tests. Manufacturing facility in China. R & D and marketing department in USA. Top Products: ACON Laboratories Mission Cholesterol Lipid Panel Meter. The perfect match for your Point Of Care clinics. Efficient: •Complete Lipid Panel test in as little as 45 seconds with 3-1 device or individual devices • One device tests for Complete Lipid Panel, including Total Cholesterol (CHOL), High Density Lipoprotein (HDL), and Triglycerides (TRIG) • Also calculates Low Density Lipoprotein (LDL), CHOL/HDL ratio, and Cardiac Risk Assessment Reliable: • Can test whole blood, serum, or plasma •Wide hematocrit range of 0-55% •Quick results ideal for physician offices, labs, and homes Easy to Use: •Large LCD display for easy reading •Color coded test devices with engraved test name for easy identification •Pending FDA 510K ACON Laboratories OnCall® Express Blood Glucose Meter. At its core, the On Call® brand is committed to the health of our customers. Carefully designed for accuracy and reliability, the On Call® Blood Glucose Meter Family has helped millions of patients worldwide effectively manage their glucose levels. The foundation for successfully managing your diabetes
Recommended publications
  • Alkermes Public Limited Company

    Alkermes Public Limited Company

    ALKERMES PUBLIC LIMITED COMPANY Directors’ Report and Consolidated Financial Statements For the Year Ended March 31, 2013 ALKERMES PLC Table of Contents Page Directors’ Report .......................................................... 2 Statement of Directors’ Responsibilities .......................................... 56 Independent Auditors’ Report—Group ........................................... 57 Consolidated Profit and Loss Account ........................................... 59 Consolidated Statement of Comprehensive Income (Loss) ............................. 60 Consolidated Balance Sheet ................................................... 61 Consolidated Statement of Cash Flows ........................................... 63 Consolidated Reconciliation of Shareholders’ Funds ................................. 62 Notes to the Consolidated Financial Statements .................................... 64 Independent Auditors’ Report—Company ......................................... 111 Company Balance Sheet ..................................................... 113 Notes to the Company Financial Statements ....................................... 114 1 DIRECTORS’ REPORT For the Year Ended March 31, 2013 The directors present their report and audited consolidated financial statements for the fiscal year ended March 31, 2013. The directors have elected to prepare the consolidated financial statements in accordance with section 1 of the Companies (Miscellaneous Provisions) Act, 2009, which provides that a true and fair view of the state of
  • In Re: Alkermes Securities Litigation 03-CV-12091-Consolidated

    In Re: Alkermes Securities Litigation 03-CV-12091-Consolidated

    Case 1:03-cv-12091-RCL Document 39 Filed 07/12/2004 Page 1 of 49 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS In re ALKERMES SECURITIES ) Master Docket No. 03-CV-12091-RCL LITIGATION ) ) CLASS ACTION This Document Relates To: ) ) ALL ACTIONS. ) ) ) CONSOLIDATED COMPLAINT FOR VIOLATION OF THE FEDERAL SECURITIES LAWS Case 1:03-cv-12091-RCL Document 39 Filed 07/12/2004 Page 2 of 49 SUMMARY AND OVERVIEW 1. This is a securities class action on behalf of all purchasers of the common stock of Alkermes, Inc. (“Alkermes” or the “Company”) between April 22, 1999 and July 1, 2002 (the “Class Period”), against Alkermes and certain of its officers and directors for violations of the Securities Exchange Act of 1934 (the “Exchange Act”). 2. Alkermes is a biopharmaceutical company focused on the development of controlled- release drug delivery technologies and their application to existing or new drug therapies. Among the drug delivery technologies defendants seek to develop are sustained-release systems based on biodegradable polymeric microspheres, including those based on Medisorb polymers. 3. In 1996, Alkermes entered into an agreement with JPI Pharmaceutical International (“Janssen”), an affiliate of pharmaceutical giant Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (“Johnson & Johnson”), to develop an injectable form of the schizophrenic drug Risperdal, based upon the Medisorb polymer technology, called Risperdal Consta. Janssen has marketed the oral form of Risperdal since 1993, with sales of $2.3 billion in 2003. According to a December 12, 2001 report by analysts Thomas Weisel Partners, LLC (“Thomas Weisel”), during the Class Period, oral Risperdal was the most prescribed drug in the $5.3 billion atypical antipsychotic market.
  • Explanation of Conflict of Interest Disclosure Parts: Part One: All

    Explanation of Conflict of Interest Disclosure Parts: Part One: All

    Explanation of Conflict of Interest Disclosure Parts: Part One: All Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical companies doing business with or proposing to do business with ACNP over past 2 years (Jan. 2011-Present) Part Two: Income Sources & Equity of $10,000 or greater Part Three: Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products or companies doing business with or proposing to do business with ACNP which constitutes more than 5% of personal income (Jan. 2011-Present): Part Four: Grants from pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products directly, or indirectly through a foundation, university, or any other organization (Jan. 2011-Present) Part Five: My primary employer is a pharmaceutical/biotech/medical device company. 2012 Program Committee Disclosures Anissa Abi-Dargham: Part 1: Pfizer; Otsuka; Takeda; Sunovion; Shire; Roche; Pierre Favre; Part 2: Pierre Favre William Carlezon: Part 1: Referring to 2010-2011: Scientific Advisory Board, Myneurolab.com; Consultant, Concert Pharmaceuticals; Consultant, Lantheus Medical Imaging; Consultant, Transcept Pharmaceuticals, (Spouse) Senior Scientist, EMD Serono; Part 2: (Spouse) Senior Scientist, EMD Serono, Part 3: (Spouse) Senior Scientist, EMD Serono Cameron Carter: Part1: GlaxoSmithKline research; Part 4: GlaxoSmithKline Karl Deisseroth: Part
  • Managing Pharmacy Automation and Informatics 271

    Managing Pharmacy Automation and Informatics 271

    Managing Pharmacy 15 Automation and Informatics Dennis A. Tribble and Mei-Jen Ho CONTENTS Framework for Health-System Pharmacy Automation .......................................... 270 Technology is a Tool ......................................................................................... 271 Be Careful: Technology Will Change the Way the Work is Performed ............ 271 Technology Requires Infrastructure .................................................................. 271 The Adoption of Pharmacy Technology Requires the Involvement of Stakeholders Outside of the Pharmacy .........................................................272 Technology Platforms are Less Important than What the Technology Can Do ...................................................................................................................272 Technology Systems Should Operate from a Single, Reliable Source of Truth on All Data .......................................................................................... 273 Interoperability is the Key to Success .......................................................... 273 Regulation of Technology and Medical Devices ................................................... 274 Other Regulatory Considerations ...................................................................... 276 State Laws .................................................................................................... 276 Drug Enforcement Agency (DEA) Regulations ...........................................277 Privacy and Security of
  • Corporate Responsibility Report

    Corporate Responsibility Report

    Corporate Responsibility Report October 2019 ©2019 Alkermes. All rights reserved. Table of Contents Section 1: Introduction . 2 Section 2: About Our Company . 3 Section 3: Our Approach to Corporate Responsibility . 4 Section 4: Environment . 6 Section 5: Social . 15 Section 6: Governance . 23 Section 7: The Future of Corporate Responsibility at Alkermes and About This Report . 27 ALKERMES • CORPORATE RESPONSIBILITY REPORT 1 SECTION 1 INTRODUCTION A Message from Our CEO Alkermes was founded by pioneers in the field of Inspired by the courage and determination of individuals neuroscience, and their legacy of innovation and in these frequently underserved and marginalized scientific excellence — applied to the real-world needs communities, we are driven to develop medicines and of patients — remains central to our mission. Alkermes contribute to systemic solutions that we hope will have technologies and discoveries have contributed to a meaningful impact on the lives of patients. important medicines that continue to shape the treatment landscape in many disease areas. Today, Our Commitment we are distinguished from other biopharmaceutical As we look toward building our business for the companies by our core focus on serious mental illness future, we are guided by the opportunity — and what and addiction — chronic, highly prevalent conditions we believe is our responsibility — to help address the that affect millions of people and represent some of unmet needs of patients and to operate in a sustainable, the most challenging public health issues of our time. socially responsible manner. We firmly believe that doing so is best for our business, our employees, for Great science. Deep compassion.
  • Implementation of a Pharmacy Automation System (Robotics) to Ensure Medication Safety at Norwalk Hospital

    Implementation of a Pharmacy Automation System (Robotics) to Ensure Medication Safety at Norwalk Hospital

    Q Manage Health Care Vol. 18, No. 2, pp. 103–114 c 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins Implementation of a Pharmacy Automation System (Robotics) to Ensure Medication Safety at Norwalk Hospital Robert J. Bepko, Jr, BS, MHA, RPh; John R. Moore, BS, MHA, RPh; John R. Coleman, PhD This article reports an intervention to improve the CURRENT INDUSTRY TRENDS quality and safety of hospital patient care by introducing the use of pharmacy robotics into the The Institute of Medicine reported in 1999 that medication distribution process. Medication safety there are more than 98 000 preventable medical er- is vitally important. The integration of pharmacy rors that occur annually in US Hospitals, that 10% robotics with computerized practitioner order entry of hospitalized patients suffer medication-related in- and bedside medication bar coding produces juries, and that more than 7000 patients die annu- ally because of medication errors.1 A recent study a significant reduction in medication errors. found that the leading cause of anxiety for patients is The creation of a safe medication—from initial the fear of suffering a medication error during their ordering to bedside administration—provides hospital stay. Evidence suggests this fear may be jus- enormous benefits to patients, to health care tified. Researchers who observed nurses delivering providers, and to the organization as well. medications to patients in 36 health care facilities in the Greater Atlantic and Denver metropolitan areas made some startling findings. Almost 1 in 5 medi- cations was given erroneously, and 7% of the mis- takes were potentially harmful.2 Investigators at Har- vard found that most medication errors occur either when a physician inaccurately ordered a medication (39%) or when a nurse administered a drug mistak- enly (38%).
  • Commercial Products

    Commercial Products

    Website www.alkermes.com Ticker Symbol (NASDAQ) ALKS Alkermes, Inc. is a fully integrated biotechnology company that develops medicines designed to yield better outcomes Contacts and improve patients’ lives. Our products, which use novel molecules and innovative drug technologies, target Rebecca Peterson Vice President, Corporate widespread diseases including central nervous system (CNS) disorders, addiction and diabetes. We approach the drug Communications development process from a patient-centric perspective, beginning with a thorough understanding of the challenges Voice: 617-583-6378 patients face on a day-to-day basis. Our products are designed with patient needs and behaviors in mind, with the goal Blair Jackson of ensuring that patients consistently take their medication for long-term treatment success. Vice President, Business Development Alkermes has multiple partnered programs and also works independently to develop and commercialize proprietary Voice: 617-250-1594 products. The company has built a wide range of capabilities, including innovative research programs, clinical development, large-scale manufacturing, and a commercial presence in the marketplace. Corporate Headquarters Alkermes, Inc. 88 Sidney Street Cambridge, MA 02139 VIVITROL® Voice: 617-494-0171 Commercial Products (naltrexone for extended-release injectable suspension) Fax: 617-494-9263 RISPERDAL® CONSTA® [(risperidone) long-acting injection] Product: VIVITROL is an injectable formulation of naltrexone, based on Alkermes’ unique Medisorb Product: RISPERDAL CONSTA is a long-acting injectable technology. VIVITROL is designed for once-monthly form of Johnson & Johnson’s schizophrenia drug, dosing, eliminating the need for patients to make a RISPERDAL. Developed utilizing Alkermes’ proprietary daily decision about taking their medicine. Alkermes Medisorb® technology, RISPERDAL CONSTA is manufactures VIVITROL at its commercial facility in Ohio administered once every two weeks, rather than daily, and markets the product independently in the U.S.
  • Central Pharmacy Automation As a Service

    Central Pharmacy Automation As a Service

    Central Pharmacy Automation as a Service A New Path Forward Executive Summary 3 Contents 1 2 Challenges of the Central Pharmacy 4 3 Goal of the Autonomous Pharmacy 5 4 Challenges to Adopting Pharmacy Automation 6 5 Technology with Service Delivers Best Outcomes 8 6 Conclusion 9 Citations 10 1 Executive The healthcare industry is undergoing a Summary monumental shift. The introduction of automation into hospital pharmacy workflows is transforming care, freeing up time for pharmacists to engage in more clinical initiatives that improve patient outcomes. The journey towards a zero-error central pharmacy reduces medication error and waste, but many pharmacies are still putting off the adoption of autonomous solutions. To overcome this reluctance, technology needs to be easy to adopt, flexible enough to adapt to the increasing complexities of the central pharmacy, and more directly establish new standards of care. Automation on its own is not enough. Hospitals and health systems must leverage new turnkey operational service models to optimize and maximize the benefit of automation technology. Leveraging new technologies within the as-a-service model will help unlock the human potential that leads to superior patient care and safety. 3 The central pharmacy is the hub of care that patients and providers depend on in any hospital facility. To keep it running smoothly, how- ever, there is a seemingly insurmountable number of challenges 2 that need to be overcome daily, stemming from a lack of inventory visibility into inventory and supply. Challenges of the The traditional solution to these challenges has been to increase Central Pharmacy administrative functions.
  • Signatory Companies

    Signatory Companies

    PhRMA Direct to Consumer Advertising Principles Signatory Companies In October 2018, the PhRMA BoArd of Directors Adopted meAsures to enhAnce the PhRMA Guiding Principles on Direct to Consumer Advertisements About Prescription Medicines. The revised, voluntAry Principles become effective on April 15, 2019. The revised, voluntAry Principles include A new guiding principle stAting thAt “[A]ll DTC television Advertising thAt identifies A prescription medicine by nAme should include direction as to where patients can find information about the cost of the medicine, such as a company- developed website, including the list price And Average, estimAted or typicAl pAtient out-of- pockets costs, or other context About the potentiAl cost of the medicine.” The Principles Also stAte thAt PhRMA will identify on its website All compAnies thAt voluntArily And independently commit to Abide by the Principles And will identify compAnies thAt complete, At the AppropriAte time, AnnuAl certificAtions thAt they hAve policies And procedures in plAce to foster compliAnce with the Principles. The following is A list of All signAtory compAnies who hAve Announced thAt they intend to Abide by the Principles: AbbVie GlAxoSmithKline Alexion Pharmaceuticals, Inc. Incyte CorporAtion Alkermes plc. Ipsen BiophArmAceuticAls, Inc. Allergan plc Johnson & Johnson Amgen Inc. Lundbeck Inc. Astellas Americas Merck & Co., Inc. AstrAZenecA PhArmAceuticAls LP NovArtis PhArmAceuticAls CorporAtion Bayer CorporAtion Novo Nordisk Inc. Biogen OtsukA AmericA PhArmAceuticAl, Inc. (OAPI) BioMArin PhArmAceuticAl Inc. Pfizer Inc Boehringer Ingelheim PharmAceuticAls, Inc. Purdue PhArmA L.P. Bristol-Myers Squibb CompAny Sanofi Celgene CorporAtion Sunovion Pharmaceuticals Inc. Daiichi SAnkyo, Inc. TakedA PhArmAceuticAls USA, Inc. EisAi Inc. TevA PhArmAceuticAls Eli Lilly And CompAny UCB EMD Serono .
  • Schedule 14A Schedule 14A Information

    Schedule 14A Schedule 14A Information

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant o Check the appropriate box: ☑ Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a- 6(e)(2)) o Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to § Rule 14a-12 ALKERMES PLC (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ☑ No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: NOT APPLICABLE (2) Aggregate number of securities to which transaction applies: NOT APPLICABLE (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): NOT APPLICABLE (4) Proposed maximum aggregate value of transaction: NOT APPLICABLE (5) Total fee paid: NOT APPLICABLE o Fee paid previously with preliminary materials: NOT APPLICABLE o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  • Oral Presentation Disclosures

    Oral Presentation Disclosures

    Oral Presentation Disclosures Adler, Lenard – Alcobra Pharma, APSARD/Pond Foundation, Major League Baseball, Major League Baseball Players Association, National Football League, New York University School of Medicine, Novartis Bioventures, Shire Pharmaceuticals, Sunovion, SUNY Upstate, Theravance, US Department of Veterans Affairs Cooperative Studies Program Anton, Raymond – Abbvie, Alkermes, Eli Lilly, Ethypharm, Lundbeck, Pfizer, Sunpharma Baker, Ross – Otsuka Pharmaceutical Development & Commercialization, Inc. Baldwin, David – Lundbeck Beaver, Jessica – Targacept, Inc. Bencherif, Merouane – Targacept, Inc. Bertolino, Alessandro – F. Hoffmann-La Roche, Ltd. Bradshaw, Mark – Euthymics Bioscience, Neurovance, Inc. Burdick, Katherine – Dainippon Sumitomo Pharma Bymaster, Frank – Euthymics Bioscience, Neurovance, Inc. Calabrese, Joseph – Sunovion, Teva (Cephalon) Cantillon, Marc – Forest, Kyowa, Lilly, Merck, Pfizer, Reviva Caroff, Stanley – Sunovion Chen, Yinzhong – Takeda Development Center Americas, Inc. Chengappa, Roy – Pfizer, Inc. Childress, Ann – Abbott Laboratories, Bristol Myer Squibb, GlaxoSmithKline, Ironshore, Janssen (Ortho-McNeil), Johnson & Johnson PRD, Lilly, Neos Therapeutics, Neurovance Inc., NextWave, Novartis, Noven, Otsuka, Pfizer, Rhodes, Sepracor, Shionogi, Shire, Somerset, Sunovion, Theravance Christine, Mazzucco – Janssen Cohen, Lee – Astra-Zeneca Pharmaceuticals, Bristol-Myers Squibb, Cephalon, Inc., GlaxoSmithKline, National Institute of Mental Health, National Institute on Aging, Noven Pharmaceuticals, Ortho-McNeil
  • Product Brochures Pharmacy Automation Brochure

    Product Brochures Pharmacy Automation Brochure

    Greater Prescription Accuracy, Improved Operating Efficiency and Lowered Costs. For Pharmacies Serving LTC/ALF/SNF Kirby Lester Are you Capsa Healthcare, which brings you Kirby Lester automation, has been a leader in Pharmacy Automation ready for medication management for extended care settings for 50+ years. from Capsa Healthcare pharmacy automation? Best-selling Medication Carts • 3 unique cart lines Automation by Capsa Healthcare • Support any med delivery (punch cards, auto If any of these challenges occur in your packaging, unit dose box) pharmacy, you will benefit from • Tremendous capacity Rx filling automation. for storing medication and supplies □ Drug diversion potential • Easily add hardware □ C-II log is a 3-ring binder for computing/EMAR, and □ Still hand-counting by 5’s accessories □ Concerned about dispensing errors • Also: In-room medication cabinets for ALF □ Pharmacy insurance company suggested “risk-minimizing technology” □ Paid too much in taxes last year □ Pharmacist time wasted by correcting Stat Dose/1st Dose and Controls filling errors Management □ Want to free up time to grow business • NexsysADC, the practical automated dispensing □ Don’t use any verification software cabinet for extended care (barcode-scanning to check the stock bottle NDC with the order’s NDC) • Fully control the onsite storage and distribution of □ Daily Rx volume is rising Greater Prescription Accuracy, meds and supplies, at a □ Hard to fill staff vacancies fraction of the cost of Improved Operating Efficiency alternative ADCs □ Pharmacy environment